H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Chromadex Corp (NASDAQ: CDXC) today and set a price target of $8. The company’s shares closed yesterday at $3.45, close to its 52-week low of $2.86.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.4% and a 40.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Chromadex Corp has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
Based on Chromadex Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.44 million. In comparison, last year the company had a GAAP net loss of $1.93 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDXC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chromadex Corp. engages in acquiring, developing, and commercializing proprietary-based ingredient technologies through its business model. It operates through the following segments: Ingredients, Core Standards and Contract Services, and Regulatory Consulting.
